Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...
Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events in patients with and without preexisting atherosclerotic cardiovascular disease (ASCVD), a new study shows. The ...
Elevated Lp(a) is a significant, often overlooked genetic risk factor for cardiovascular disease, affecting 1 in 5 Americans. The AHA's Lp(a) Community Health Centers Discovery Project aims to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results